Gland B2B Business Model and Growth Strategy

Domestic Market 9 Domestic market sales remain steady and have shown 19% growth in FY21 ■ The new capacities being made available for the domestic market has helped ramp up volume growth in the core portfolio of products ■ We ramped up Remdesivir supply for the domestic market considering the requirement for Indian patients ■ New launches: FY21: 10 Product SKUs (6 molecules) FY21: Rs. 5,564 Mn YoY Growth: 19% Q4 FY21: Rs. 1,248 Mn YoY Growth: 15% Domestic Indian Market FY20 Revenue Contribution 18% 16% FY21 GLAND

View entire presentation